Exact Sciences logo

Exact SciencesNASDAQ: EXAS

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 February 2001

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$9.73 B
-47%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
69%vs. sector
-58%vs. 3y high
54%vs. sector

Price

after hours | 39 min ago
$52.56-$1.93(-3.54%)

Dividend

No data over the past 3 years
$708.65 M$698.46 M
$708.65 M-$38.24 M

Analysts recommendations

Institutional Ownership

EXAS Latest News

Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
seekingalpha.com19 November 2024 Sentiment: POSITIVE

Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
zacks.com18 November 2024 Sentiment: POSITIVE

Exact Sciences presents new positive evidence backing the development of an MCED test.

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
businesswire.com13 November 2024 Sentiment: POSITIVE

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening m.

Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
zacks.com06 November 2024 Sentiment: POSITIVE

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.

Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
investopedia.com06 November 2024 Sentiment: NEGATIVE

Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.

Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
zacks.com29 October 2024 Sentiment: POSITIVE

Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
businesswire.com27 October 2024 Sentiment: POSITIVE

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG takes place October 25-30, 2024, in Philadelphia, Pennsylvania. Exact Sciences will also present new data on improving a.

Will Screening Sales Drive Exact Sciences' Q3 Earnings?
zacks.com22 October 2024 Sentiment: POSITIVE

Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
zacks.com10 October 2024 Sentiment: POSITIVE

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
zacks.com04 October 2024 Sentiment: POSITIVE

Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.

What type of business is Exact Sciences?

Exact Sciences Corporation is one of the leading companies in the development of tests for the diagnosis of oncological diseases. It is the developer of several of the most effective test brands in the field of cancer screening and diagnosis - including Cologuard (diagnosis of colorectal cancer) and Oncotype DX (diagnosis of breast, prostate, and colon cancer). Currently, they are working on creating additional tests for other types of cancer. The company was founded in 1995. The headquarters are located in Madison, Wisconsin. Exact has agreements for cooperation and licensing with the Mayo Clinic Foundation for Medical Education and Research, licensing agreements with Hologic, Biocartis, Epic Sciences, and others.

What sector is Exact Sciences in?

Exact Sciences is in the Healthcare sector

What industry is Exact Sciences in?

Exact Sciences is in the Diagnostics & Research industry

What country is Exact Sciences from?

Exact Sciences is headquartered in United States

When did Exact Sciences go public?

Exact Sciences initial public offering (IPO) was on 01 February 2001

What is Exact Sciences website?

https://www.exactsciences.com

Is Exact Sciences in the S&P 500?

No, Exact Sciences is not included in the S&P 500 index

Is Exact Sciences in the NASDAQ 100?

No, Exact Sciences is not included in the NASDAQ 100 index

Is Exact Sciences in the Dow Jones?

No, Exact Sciences is not included in the Dow Jones index

When was Exact Sciences the previous earnings report?

No data

When does Exact Sciences earnings report?

The next expected earnings date for Exact Sciences is 21 February 2025